Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

被引：0
作者：
Carole Dembek
Leigh Ann White
Jayson Quach
Andrea Szkurhan
Nazia Rashid
M. R. Blasco
机构：
[1] Avalere Health,
[2] Biogen Idec,undefined
[3] Dymaxium,undefined
[4] Hospital Universitario Puerta de Hierro,undefined
来源：
The European Journal of Health Economics | 2014年 / 15卷
关键词：
Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 362
页数：9
相关论文
共 86 条
[31]  
Bell C(1982)Course of multiple sclerosis: first results of a prospective study carried out of 102 MS patients from 1976–1980 Acta Neurol Scand 65 248-364
[32]  
Graham J(2008)Quantitative risk-benefit analysis of natalizumab Neurology 71 357-208
[33]  
Earnshaw S(1990)EuroQol—a new facility of the measurement of health-related quality of life Health Policy 16 199-17
[34]  
Chilcott J(2003)Principles of good practice for decision analytic modeling in health care evaluation: report of the ISPOR task force on good research practices—modeling studies Value Health 6 9-371
[35]  
McCabe C(2006)Good practice guidelines for decision-analytic modelling in health technology assessment Pharmacoeconomics 24 355-undefined
[36]  
Tappenden P(undefined)undefined undefined undefined undefined-undefined
[37]  
Goldberg LD(undefined)undefined undefined undefined undefined-undefined
[38]  
Edwards NC(undefined)undefined undefined undefined undefined-undefined
[39]  
Fincher C(undefined)undefined undefined undefined undefined-undefined
[40]  
Guo S(undefined)undefined undefined undefined undefined-undefined
123456789